Amarin shares slump as surprising court defeat puts Vascepa at risk

In what one analyst called a "serious blow," a federal court ruled patents held by Amarin on its heart drug Vascepa were obvious and therefore invalid. 

Amarin shares slump as surprising court defeat puts Vascepa at risk
In what one analyst called a "serious blow," a federal court ruled patents held by Amarin on its heart drug Vascepa were obvious and therefore invalid.